Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists use gut bacteria to predict cancer treatment success

NCT ID NCT07346729

Knowledge-focused Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 60 people with advanced rectal cancer to see if the bacteria in their gut and mouth could predict how well they respond to chemotherapy and radiation before surgery. Researchers collected stool and saliva samples before treatment and used machine learning to analyze the bacteria. The goal was to build a model that could forecast tumor shrinkage, potentially helping doctors personalize cancer care in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple stool or saliva test to predict which rectal cancer patients will benefit most from chemoradiotherapy, personalizing treatment.
What could go wrong
This is a small, observational study (60 people) that only looks for patterns. It does not test a treatment, so any predictions need much larger studies to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Jun 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Locally Advanced Rectal Cancer

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Voluntary signing of informed consent form 2. Age range: 18-75 years old 3. Diagnosed by histopathological examination and indicated by comprehensive evaluation for neoadjuvant radiotherapy and chemotherapy in locally advanced rectal cancer patients 4. Immunohistochemistry or genetic testing for MSS 5. Imaging shows no distant metastatic lesions 6. ECOG score 0-1 7. All patients are required to complete neoadjuvant concurrent chemoradiotherapy and intraoperative chemotherapy at our center, and return to the hospital on schedule for preoperative evaluation and tumor resection surgery 8. After inspection and evaluation, there is normal bone marrow hematopoiesis, liver and kidney function Exclusion Criteria: 1. Previously received anti-tumor treatment 2. History of other malignant tumors 3. Imaging confirms the presence of distant metastases 4. Patients with MSI-H or dMMR rectal cancer detected by immunohistochemistry or genetic testing 5. Used probiotics, antibiotics, prebiotics, immunosuppressants, and glucocorticoids within the 4 weeks 6. Pathological tissue specimens without assessable efficacy of neoadjuvant therapy 7. Change treatment plan due to disease progression or severe treatment side effects 8. According to the researcher's judgment, it is not suitable to participate in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rectal cancer

Contacts and locations

Locations

  • Nanfang Hosptial

    Guangzhou, Guangdong, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.